Product Code: IRTNTR10443
About AMD
AMD is the degeneration or disintegration of the eye's macula. The macula is a small area of the retina that is responsible for the central vision. AMD can be classified into two types: dry and wet macular degenerations. When the tiny abnormal blood vessels begin growing toward the macula, it develops into wet AMD. Dry AMD occurs when small, yellowish deposits called drusen start accumulating beneath the macula. While some treatments are available for wet AMD; there is no treatment available at the moment for dry AMD.
Technavio's analysts forecast the global age-related macular degeneration (AMD) market to grow at a CAGR of 7.37% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global age-related macular degeneration (AMD) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of AMD.
The market is divided into the following segments based on geography:
Technavio's report, Global Age-Related Macular Degeneration (AMD) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Bayer HealthCare
- F. Hoffmann-La Roche
- Novartis
- Regeneron Pharmaceuticals
Other Prominent Vendors
- Alcon
- Allergan
- Adverum Biotechnologies
- Bausch + Lomb
- Gilead Sciences
- Iconic Therapeutics
- Lpath
- Neurotech Pharmaceuticals
- Ohr Pharmaceutical
- Opthea
- Ophthotech
- PanOptica
- Pfizer
- Promedior
- QLT
- Quark
- Resolvyx Pharmaceuticals
- RXi Pharmaceuticals
- Sagent Pharmaceuticals
- Santen Pharmaceuticals
- Sanwa Kagaku Kenkyusho
Market driver
- Increasing reimbursement benefits for AMD drugs
- For a full, detailed list, view our report
Market challenge
- Availability of alternative therapies
- For a full, detailed list, view our report
Market trend
- Novel treatment approaches for developing AMD drugs
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Key buying criteria
PART 06: AMD: Overview
- Understanding the disease
- Stages of AMD
- Etiology
- Signs and symptoms
- Diagnosis
- Management
PART 07: Pipeline portfolio
PART 08: Market landscape
PART 09: Market analysis of major drugs
- Lucentis
- Eylea
- Avastin
- Five forces analysis
PART 10: Market segmentation by type
- Global wet AMD market
- Market overview
- Global dry AMD market
- Market overview
PART 11: Market segmentation by ROA
PART 12: Geographical segmentation
- AMD market in Americas
- AMD market in EMEA
- AMD market in APAC
PART 13: Market drivers
- Increase in aging population
- Increasing reimbursement benefits for AMD drugs
- Increase in diagnosis rate
- High patient and physician satisfaction
PART 14: Impact of drivers
PART 15: Market challenges
- Gap in patient demand vs. ophthalmology expert supply
- Increasing use of off-label drugs
- Availability of alternative therapies
PART 16: Impact of drivers and challenges
PART 17: Market trends
- Novel treatment approaches for developing AMD drugs
- Increased research grants, initiatives, and programs
- Use of combination therapies
PART 18: Vendor landscape
- Competitive scenario
- Other prominent vendors
PART 19: Key vendor analysis
- Bayer HealthCare
- F. Hoffmann-La Roche
- Novartis
- Regeneron Pharmaceuticals
PART 20: Appendix
PART 21: Explore Technavio
List of Exhibits
- Exhibit 01: Product offerings
- Exhibit 02: Leading drugs for AMD
- Exhibit 03: Novel opportunities for AMD market: Entry of squalamine
- Exhibit 04: Global AMD market snapshot
- Exhibit 05: Key buying criteria for AMD drugs
- Exhibit 06: Key buying criteria for global AMD market 2015
- Exhibit 07: Impact of key customer segments on global AMD market 2015
- Exhibit 08: Stages of AMD
- Exhibit 09: Risk factors for AMD
- Exhibit 10: Diagnosis of AMD
- Exhibit 11: Product portfolio of current AMD therapies
- Exhibit 12: Share of pipeline molecules in global AMD market
- Exhibit 13: Prevalence of AMD 2000 and 2050 (millions)
- Exhibit 14: Global AMD market snapshot: Developed and emerging markets 2015
- Exhibit 15: Factors influencing the global AMD market 2015
- Exhibit 16: Global AMD market 2015-2020 ($ billions)
- Exhibit 17: Impact of drivers and challenges of global AMD market
- Exhibit 18: Opportunity analysis of global AMD market by type
- Exhibit 19: Timeline of key regulatory approvals of Lucentis
- Exhibit 20: YoY growth and revenue generated from sales of Lucentis 2013-2015 ($ billions)
- Exhibit 21: Timeline of key regulatory approvals and filings of Eylea
- Exhibit 22: YoY revenue and growth rate of Eylea 2012-2015 ($ billions)
- Exhibit 23: Five forces analysis
- Exhibit 24: Global AMD market: Segmentation by type 2015-2020
- Exhibit 25: Global AMD market segmentation: Growth cycle analysis
- Exhibit 26: Competitive landscape of wet AMD drugs
- Exhibit 27: Global wet AMD market 2015-2020 ($ billions)
- Exhibit 28: Opportunity analysis of global dry AMD market
- Exhibit 29: Global dry AMD market 2015-2020 ($ millions)
- Exhibit 30: Segmentation of global AMD market by ROA 2015
- Exhibit 31: Global AMD market: Geographical outlook (2015-2020)
- Exhibit 32: Global AMD market: Geography outlook 2015
- Exhibit 33: Revenue/growth outlook in different countries/regions 2015
- Exhibit 34: Global AMD market segmentation by region: Market growth lifecycle analysis 2015
- Exhibit 35: AMD market revenue by geography 2015-2020 ($ billions)
- Exhibit 36: Opportunity analysis of AMD market in Americas
- Exhibit 37: AMD market in Americas 2015-2020 ($ billions)
- Exhibit 38: Opportunity analysis of AMD market in EMEA
- Exhibit 39: AMD market in EMEA 2015-2020 ($ billions)
- Exhibit 40: Opportunity analysis of AMD market in APAC
- Exhibit 41: Prevalence rates of AMD in APAC countries 2015
- Exhibit 42: AMD market in APAC 2015-2020 ($ billions)
- Exhibit 43: Percentage of Americans with vision loss
- Exhibit 44: Distribution of population aged 60 years and over (millions)
- Exhibit 45: Impact of drivers
- Exhibit 46: Impact of drivers and challenges
- Exhibit 47: Geographical presence of key vendors
- Exhibit 48: Company portfolio analysis in global AMD market 2016-2020
- Exhibit 49: Bayer HealthCare: Profile
- Exhibit 50: Bayer HealthCare: Metrics analysis
- Exhibit 51: Bayer HealthCare: Growth strategy matrix
- Exhibit 52: Bayer HealthCare: Opportunity assessment
- Exhibit 53: F. Hoffmann-La Roche: Profile
- Exhibit 54: F. Hoffmann-La Roche: Metrics analysis
- Exhibit 55: F. Hoffmann-La Roche: Growth strategy matrix
- Exhibit 56: F. Hoffmann-La Roche: Opportunity assessment
- Exhibit 57: Novartis: Specialty ophthalmic segmentation by revenue 2015
- Exhibit 58: Novartis: Profile
- Exhibit 59: Novartis: Metrics analysis
- Exhibit 60: Novartis: Growth strategy matrix
- Exhibit 61: Novartis: Opportunity assessment
- Exhibit 62: Regeneron Pharmaceuticals: Profile
- Exhibit 63: Regeneron Pharmaceuticals: Metrics analysis
- Exhibit 64: Regeneron Pharmaceuticals: Growth strategy matrix
- Exhibit 65: Regeneron Pharmaceuticals: Growth opportunity assessment
